Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MetMAb Plus Chemotherapy in First-Line Non-Squamous NSCLC
NCT01496742Phase 2Completed
- Sponsor
- Genentech
- Start
- Apr 2012
- Primary completion
- Nov 2015
- Modality
- Monoclonal Antibodies
- Countries
- 13
01
Overview
A Phase 2 trial of onartuzumab in Nonsquamous Non-Small Cell Lung Cancer (nsNSCLC), sponsored by Genentech. Started Apr 2012; status: completed.
02
Drugs
onartuzumab
03
Conditions
Nonsquamous Non-Small Cell Lung Cancer (nsNSCLC)
Beyond the preview
Go deeper on NCT01496742.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01496742.